\-\ Texto\\:\\ \ \(0\)\
\-\ cr\\ 2\\.4\\,\\ bun\\ 5\\.5\\ \\(baseline\\ cr\\ 1\\.6\\,\\ bun\\ 29\\)\ \(0\)\
\-\ ua\\-\\ 26\\ wbcs\\/hpf\\,\\ blood\\ 25\\/ul\\,\\ 2\\+\\ leukocyte\\ esterase\\ and\\ many\\ bacteria\\/hpf\ \(0\)\
\-\ the\\ patient\\ underwent\\ an\\ exploratory\\ laparotomy\\ with\\ resection\\ of\\ the\\ mass\\,\\ juxtarenal\\ ivc\\,\\ right\\ kidney\\,\\ and\\ right\\ adrenal\\ gland\\ with\\ graft\\ revision\\ of\\ the\\ juxtarenal\\ ivc\\.\\ \\ she\\ was\\ discharged\\ without\\ complication\\ on\\ post\\-operative\\ day\\ 5\\ with\\ scheduled\\ follow\\-up\\.\ \(0\)\
\-\ abdominal\\ ct\\ with\\ iv\\ contrast\\ reveals\\ a\\ 5x7x8cm\\ retroperitoneal\\ mass\\ at\\ the\\ level\\ of\\ the\\ juxtarenal\\ ivc\\ and\\ right\\ hydronephrosis\\.\\ \\ inferior\\ vena\\ caval\\ venography\\ reveals\\ total\\ ivc\\ occlusion\\ below\\ the\\ renal\\ veins\\ to\\ the\\ retrohepatic\\ region\\ with\\ significant\\ venous\\ collateralization\\.\ \(0\)\
\-\ pathology\\ consistent\\ with\\ leiomyosarcoma\\.\ \(0\)\
\-\ angiosarcoma\\,\\ leiomyosarcoma\\,\\ leiomyomatosis\\,\\ and\\ neurogenic\\ tumor\\ such\\ as\\ paraganglioma\ \(0\)\
\-\ 69\\ y\\/o\\ african\\-american\\ female\\ with\\ a\\ history\\ of\\ chronic\\ renal\\ insufficiency\\ and\\ hypertension\\ presented\\ with\\ a\\ 2\\ month\\ history\\ of\\ worsening\\ low\\ back\\ pain\\.\ \(0\)\
\-\ inferior\\ vena\\ cava\\ leiomyosarcoma\\ is\\ a\\ rare\\ tumor\\ representing\\ approximately\\ 0\\.5\\%\\ of\\ all\\ adult\\ soft\\ tissue\\ sarcomas\\.\\ \\ presenting\\ symptoms\\,\\ management\\,\\ and\\ prognosis\\ are\\ related\\ to\\ tumor\\ location\\.\\ \\ upper\\ ivc\\ leiomyosarcomas\\ occur\\ superior\\ to\\ the\\ hepatic\\ vein\\,\\ present\\ with\\ budd\\-chiari\\ syndrome\\,\\ and\\ are\\ the\\ least\\ amenable\\ to\\ resection\\ resulting\\ in\\ the\\ worst\\ prognosis\\.\\ \\ middle\\ ivc\\ leiomyosarcomas\\ occur\\ between\\ the\\ hepatic\\ and\\ renal\\ veins\\,\\ may\\ present\\ with\\ right\\ upper\\ quadrant\\ pain\\ or\\ renovascular\\ hypertension\\,\\ and\\ have\\ improved\\ survival\\.\\ \\ lower\\ ivc\\ leiomyosarcomas\\ occur\\ inferior\\ to\\ the\\ renal\\ vein\\,\\ may\\ present\\ with\\ right\\ lower\\ quadrant\\,\\ back\\,\\ or\\ flank\\ pain\\ or\\ lower\\ extremity\\ edema\\,\\ are\\ the\\ most\\ amenable\\ to\\ complete\\ resection\\,\\ and\\ have\\ the\\ best\\ prognosis\\.\\ \\ 5\\ year\\ survival\\ among\\ all\\ patients\\ has\\ been\\ reported\\ to\\ be\\ 33\\-53\\%\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ivc\\:\\ 0\\.1080334570456823\ \(0\)\
\-\ juxtarenal\\:\\ 0\\.08964933990474404\ \(0\)\
\-\ leiomyosarcomas\\:\\ 0\\.08964933990474404\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.05733014840968019\ \(0\)\
\-\ amenable\\:\\ 0\\.04566831784601127\ \(0\)\
\-\ prognosis\\:\\ 0\\.04122045243222449\ \(0\)\
\-\ renal\\:\\ 0\\.03481322778926196\ \(0\)\
\-\ cr\\:\\ 0\\.034756874371881775\ \(0\)\
\-\ occur\\:\\ 0\\.03260386402150717\ \(0\)\
\-\ bun\\:\\ 0\\.03200795838470778\ \(0\)\
\-\ survival\\:\\ 0\\.03106041979233382\ \(0\)\
\-\ vena\\:\\ 0\\.030678365985207505\ \(0\)\
\-\ 25\\/ul\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ 5x7x8cm\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ retrohepatic\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ 33\\-53\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ inferior\\:\\ 0\\.02948457316636335\ \(0\)\
\-\ veins\\:\\ 0\\.027716139696638355\ \(0\)\
\-\ wbcs\\/hpf\\:\\ 0\\.02753346184205611\ \(0\)\
\-\ resection\\:\\ 0\\.027100837174781883\ \(0\)\
\-\ bacteria\\/hpf\\:\\ 0\\.02615900384846911\ \(0\)\
\-\ leiomyomatosis\\:\\ 0\\.02615900384846911\ \(0\)\
\-\ renovascular\\:\\ 0\\.02615900384846911\ \(0\)\
\-\ ua\\-\\:\\ 0\\.025183810382530872\ \(0\)\
\-\ caval\\:\\ 0\\.025183810382530872\ \(0\)\
\-\ hepatic\\:\\ 0\\.024193182046142455\ \(0\)\
\-\ hypertension\\:\\ 0\\.02283919357491653\ \(0\)\
\-\ venography\\:\\ 0\\.022834158923005634\ \(0\)\
\-\ collateralization\\:\\ 0\\.022834158923005634\ \(0\)\
\-\ reveals\\:\\ 0\\.022666086442678122\ \(0\)\
\-\ budd\\-chiari\\:\\ 0\\.022077740104991365\ \(0\)\
\-\ revision\\:\\ 0\\.021459700929418634\ \(0\)\
\-\ sarcomas\\:\\ 0\\.021188369716965968\ \(0\)\
\-\ vein\\:\\ 0\\.0209622598102652\ \(0\)\
\-\ esterase\\:\\ 0\\.020703282111404365\ \(0\)\
\-\ quadrant\\:\\ 0\\.020388989382956302\ \(0\)\
\-\ tumor\\:\\ 0\\.020259989507906553\ \(0\)\
\-\ leukocyte\\:\\ 0\\.019901964219661214\ \(0\)\
\-\ exploratory\\:\\ 0\\.019901964219661214\ \(0\)\
\-\ 5\\.5\\:\\ 0\\.019728088645466126\ \(0\)\
\-\ angiosarcoma\\:\\ 0\\.019728088645466126\ \(0\)\
\-\ present\\:\\ 0\\.019627207667101836\ \(0\)\
\-\ lower\\:\\ 0\\.01954436002742911\ \(0\)\
\-\ \\,\\:\\ 0\\.019270886019874697\ \(0\)\
\-\ back\\:\\ 0\\.019112314137948998\ \(0\)\
\-\ worst\\:\\ 0\\.018971669827451854\ \(0\)\
\-\ laparotomy\\:\\ 0\\.01871078494224464\ \(0\)\
\-\ african\\-american\\:\\ 0\\.01871078494224464\ \(0\)\
\-\ 69\\:\\ 0\\.01824247871010628\ \(0\)\
\-\ 1\\.6\\:\\ 0\\.018134856003955157\ \(0\)\
\-\ 2\\.4\\:\\ 0\\.018030545296610228\ \(0\)\
\-\ paraganglioma\\:\\ 0\\.017929348811357073\ \(0\)\
\-\ 0\\.5\\:\\ 0\\.017929348811357073\ \(0\)\
\-\ neurogenic\\:\\ 0\\.01783108597449859\ \(0\)\
\-\ among\\:\\ 0\\.017213046798925862\ \(0\)\
\-\ baseline\\:\\ 0\\.017133282400925206\ \(0\)\
\-\ graft\\:\\ 0\\.017133282400925206\ \(0\)\
\-\ 5\\:\\ 0\\.016950240152163818\ \(0\)\
\-\ post\\-operative\\:\\ 0\\.01676039801036816\ \(0\)\
\-\ all\\:\\ 0\\.016385921962246038\ \(0\)\
\-\ retroperitoneal\\:\\ 0\\.015433351006526043\ \(0\)\
\-\ insufficiency\\:\\ 0\\.015385940016781162\ \(0\)\
\-\ right\\:\\ 0\\.015281893374752826\ \(0\)\
\-\ cava\\:\\ 0\\.01524756037433962\ \(0\)\
\-\ 29\\:\\ 0\\.015114608804328496\ \(0\)\
\-\ representing\\:\\ 0\\.014945081954922864\ \(0\)\
\-\ 2\\+\\:\\ 0\\.014823278533817565\ \(0\)\
\-\ adrenal\\:\\ 0\\.014667396794014775\ \(0\)\
\-\ scheduled\\:\\ 0\\.014592064126947961\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.014592064126947961\ \(0\)\
\-\ adult\\:\\ 0\\.01451836925699404\ \(0\)\
\-\ least\\:\\ 0\\.01451836925699404\ \(0\)\
\-\ occlusion\\:\\ 0\\.014446242482596466\ \(0\)\
\-\ complication\\:\\ 0\\.014205239358244836\ \(0\)\
\-\ upper\\:\\ 0\\.013980206816059108\ \(0\)\
\-\ improved\\:\\ 0\\.0137985976122144\ \(0\)\
\-\ flank\\:\\ 0\\.013626196197863583\ \(0\)\
\-\ \\%\\:\\ 0\\.01351404090404073\ \(0\)\
\-\ 26\\:\\ 0\\.01340917294781297\ \(0\)\
\-\ discharged\\:\\ 0\\.013280266522086734\ \(0\)\
\-\ resulting\\:\\ 0\\.012721774206574683\ \(0\)\
\-\ may\\:\\ 0\\.0127073109755805\ \(0\)\
\-\ below\\:\\ 0\\.012574823559545483\ \(0\)\
\-\ have\\:\\ 0\\.012545342904170113\ \(0\)\
\-\ total\\:\\ 0\\.012473627074292325\ \(0\)\
\-\ gland\\:\\ 0\\.012336843021670063\ \(0\)\
\-\ best\\:\\ 0\\.012186991860637876\ \(0\)\
\-\ related\\:\\ 0\\.011956784383972756\ \(0\)\
\-\ many\\:\\ 0\\.011905808528499737\ \(0\)\
\-\ pathology\\:\\ 0\\.0118555878987196\ \(0\)\
\-\ are\\:\\ 0\\.011846174974877305\ \(0\)\
\-\ presenting\\:\\ 0\\.011806100443054674\ \(0\)\
\-\ worsening\\:\\ 0\\.011405016848816263\ \(0\)\
\-\ rare\\:\\ 0\\.01124864474126541\ \(0\)\
\-\ management\\:\\ 0\\.010930615062561495\ \(0\)\
\-\ pain\\:\\ 0\\.010612964415566794\ \(0\)\
\-\ middle\\:\\ 0\\.010593759219126907\ \(0\)\
\-\ extremity\\:\\ 0\\.010593759219126907\ \(0\)\
\-\ iv\\:\\ 0\\.010570931991393537\ \(0\)\
\-\ reported\\:\\ 0\\.01055957576466377\ \(0\)\
\-\ venous\\:\\ 0\\.010514527520193658\ \(0\)\
\-\ kidney\\:\\ 0\\.010204689678135625\ \(0\)\
\-\ complete\\:\\ 0\\.010194494691478151\ \(0\)\
\-\ or\\:\\ 0\\.0101849771081055\ \(0\)\
\-\ to\\:\\ 0\\.010133819522375945\ \(0\)\
\-\ location\\:\\ 0\\.010104093853911502\ \(0\)\
\-\ underwent\\:\\ 0\\.009939647577892268\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.00942385420827709\ \(0\)\
\-\ superior\\:\\ 0\\.009249978634082005\ \(0\)\
\-\ day\\:\\ 0\\.00919647399780654\ \(0\)\
\-\ between\\:\\ 0\\.009181340800760149\ \(0\)\
\-\ such\\:\\ 0\\.009055365389291024\ \(0\)\
\-\ approximately\\:\\ 0\\.00896209432730706\ \(0\)\
\-\ month\\:\\ 0\\.008690218782374947\ \(0\)\
\-\ level\\:\\ 0\\.008348776364904853\ \(0\)\
\-\ syndrome\\:\\ 0\\.00828442907367675\ \(0\)\
\-\ edema\\:\\ 0\\.008192960981123019\ \(0\)\
\-\ region\\:\\ 0\\.0081816990753875\ \(0\)\
\-\ chronic\\:\\ 0\\.00815928689121017\ \(0\)\
\-\ she\\:\\ 0\\.008131478445607363\ \(0\)\
\-\ mass\\:\\ 0\\.008057362758966539\ \(0\)\
\-\ low\\:\\ 0\\.00805480695886915\ \(0\)\
\-\ y\\/o\\:\\ 0\\.008022471287524206\ \(0\)\
\-\ history\\:\\ 0\\.00800145449292938\ \(0\)\
\-\ blood\\:\\ 0\\.00790647821189593\ \(0\)\
\-\ presented\\:\\ 0\\.00789612757634715\ \(0\)\
\-\ been\\:\\ 0\\.007880660642250818\ \(0\)\
\-\ significant\\:\\ 0\\.007789312376454994\ \(0\)\
\-\ patients\\:\\ 0\\.007496863048698393\ \(0\)\
\-\ abdominal\\:\\ 0\\.007240404197024119\ \(0\)\
\-\ symptoms\\:\\ 0\\.007219177887790302\ \(0\)\
\-\ consistent\\:\\ 0\\.007102705996037977\ \(0\)\
\-\ soft\\:\\ 0\\.00705398903048661\ \(0\)\
\-\ tissue\\:\\ 0\\.006865834537127436\ \(0\)\
\-\ without\\:\\ 0\\.006820383614773424\ \(0\)\
\-\ most\\:\\ 0\\.006687576751620596\ \(0\)\
\-\ the\\:\\ 0\\.006560983002883936\ \(0\)\
\-\ contrast\\:\\ 0\\.006483985379009848\ \(0\)\
\-\ 2\\:\\ 0\\.006237642361052699\ \(0\)\
\-\ and\\:\\ 0\\.0061020001943124895\ \(0\)\
\-\ female\\:\\ 0\\.005955119564229944\ \(0\)\
\-\ has\\:\\ 0\\.005439660916929756\ \(0\)\
\-\ a\\:\\ 0\\.005377624431438661\ \(0\)\
\-\ be\\:\\ 0\\.004466971943538743\ \(0\)\
\-\ as\\:\\ 0\\.004381618664047891\ \(0\)\
\-\ with\\:\\ 0\\.004362867583012838\ \(0\)\
\-\ ct\\:\\ 0\\.004051876791159467\ \(0\)\
\-\ an\\:\\ 0\\.004005643607744846\ \(0\)\
\-\ at\\:\\ 0\\.003924620857056383\ \(0\)\
\-\ was\\:\\ 0\\.0033500932956396163\ \(0\)\
\-\ year\\:\\ 0\\.003241034811094626\ \(0\)\
\-\ patient\\:\\ 0\\.0029037014607335185\ \(0\)\
\-\ on\\:\\ 0\\.002453867838526875\ \(0\)\
\-\ \\(\\:\\ 0\\.002448683817775798\ \(0\)\
\-\ \\)\\:\\ 0\\.0024187718376722208\ \(0\)\
\-\ of\\:\\ 0\\.002369568829789595\ \(0\)\
\-\ is\\:\\ 0\\.0019060704352024597\ \(0\)\
\-\ \\.\\:\\ 0\\.0014440489259937466\ \(0\)\
\-\ in\\:\\ 0\\.0014284651869161183\ \(0\)\
